Germany's Stada has received a third, higher takeover offer
Reuters
Published Feb 16, 2017 06:21PM ET
Germany's Stada has received a third, higher takeover offer
FRANKFURT (Reuters) - German generic drugs company Stada (DE:STAGn) said on Thursday it had received its third takeover approach, and at 58 euros ($61.89) per share, the latest offer was two euros higher than rival suitor Cinven Partners' offer.
The company said earlier this week that Cinven, a private equity investment firm, had offered 56 euros per share. Private equity firm Advent International was the second prospective bidder though a price has not been disclosed.
Stada did not identify the third suitor.
The bidding contest for 122-year-old Stada is intensifying as Advent is expected to submit a bid next week, two sources in the financial industry said. Advent declined comment.
Stada, based near Frankfurt, said earlier this week it had invited Cinven and Advent to the negotiating table after months of courtship.
The third investor is a major international private equity firm, a person familiar with the matter said. Its non-binding expression of interest valued Stada at 3.6 billion euros, 100 million euros more than Cinven's offer.
Seeking investments in stable healthcare businesses, cash-rich buyout firms - also including Permira (UL:PERM) and CVC (UL:CVC) - have been working on offers for months and approached Stada about a deal, people familiar with the situation told Reuters. Bain Capital is viewed by observers as another prospective acquirer.
Spokespeople for Permira, CVC and Bain declined comment.
A meeting of the supervisory board has been arranged for Friday at short notice, a source close to the board said, with the M&A process expected to be on the agenda.
Founded in 1895 in Dresden as a pharmacists' cooperative, Stada is seeking to expand its non-prescription consumer care business. Its generic drug business is under price pressure as medical insurers in Germany, its largest market, are seeking bulk procurement deals at low prices.
($1 = 0.9371 euros)
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.